Delivery Order SPE2DB24D2205-SPE2DB25FEGCZ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $17,238.33 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen auto-injectors. This competitively awarded, firm fixed-price delivery order was issued on July 28, 2025, with an ultimate completion date of July 29, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting open competition among qualified pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $20,876.59 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 14, 2025, with an ultimate completion date of August 15, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded contract supporting the federal government's pharmaceutical supply chain. The contract will be performed at AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded a delivery order valued at $36,944.08 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 14, 2025, with completion scheduled for August 15, 2025. This firm fixed price, competitively awarded delivery order represents a direct fulfillment under the company's existing pharmaceutical supply agreement with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at approximately $15.5K to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injections on August 4, 2025, with completion expected by August 5, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a delivery order valued at $11,853.51 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injections on July 31, 2025, with an ultimate completion date of August 1, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The pharmaceutical will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen Drug Corp's corporate headquarters. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $12,151.38 to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL pen injectors on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through...
- The Defense Logistics Agency awarded a $5,143.88 delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with an ultimate completion date of August 4, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to AmerisourceBergen's Corporate Office division based in Conshohocken, Pennsylvania. The contract represents a small-value transaction within AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a $29,850.86 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. The contract, designated as a firm fixed price delivery order with an ultimate completion date of July 28, 2025, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's established...
- On August 5, 2025, the Defense Logistics Agency awarded a delivery order valued at $48,364.69 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injections. This firm fixed-price delivery order, which is not set-aside designated, represents a competitive award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The products will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $18,639.00 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors. The contract was awarded on August 13, 2025, with an ultimate completion date of August 14, 2025, and uses firm fixed pricing with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office location. This delivery order represents a competitive award to the...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEGCZDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $56,673.62 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen auto-injectors on August 12, 2025. This firm fixed-price delivery order, which is neither set-aside nor restricted, will be fulfilled from the vendor's location in Conshohocken, Pennsylvania, with an ultimate completion date of August 13, 2025. The award represents a routine pharmaceutical procurement under the agency's medical supply chain operations to support federal healthcare needs. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical vendor in the federal medical procurement ecosystem, AmerisourceBergen Drug Corp supplies a comprehensive range of brand-name and generic medications, vaccines, and specialized medical supplies to support military and veteran healthcare systems. The parent IDC serves as a flexible vehicle enabling the company to fulfill pharmaceutical requirements across multiple therapeutic domains for customers including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $56.7k | 8/12/25 |